Wall Street brokerages forecast that Biogen Inc. (NASDAQ:BIIB – Get Rating) will report sales of $2.50 billion for the current fiscal quarter, Zacks Investment Research reports. Twenty Nine analysts have issued estimates for Biogen’s earnings, with the lowest sales estimate coming in at $2.36 billion and the highest estimate coming in at $2.60 billion. Biogen reported sales of $2.78 billion in the same quarter last year, which would suggest a negative year over year growth rate of 10.1%. The company is expected to announce its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that Biogen will report full-year sales of $9.84 billion for the current fiscal year, with estimates ranging from $9.67 billion to $10.04 billion. For the next fiscal year, analysts expect that the firm will report sales of $9.49 billion, with estimates ranging from $8.68 billion to $10.58 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Biogen.
Biogen (NASDAQ:BIIB – Get Rating) last posted its quarterly earnings data on Tuesday, May 3rd. The biotechnology company reported $3.62 earnings per share for the quarter, missing analysts’ consensus estimates of $4.41 by ($0.79). Biogen had a net margin of 13.40% and a return on equity of 23.46%. The firm had revenue of $2.53 billion during the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter last year, the business earned $5.34 earnings per share. The business’s quarterly revenue was down 6.1% on a year-over-year basis.
NASDAQ:BIIB opened at $199.65 on Monday. The company has a market capitalization of $29.24 billion, a PE ratio of 20.44, a price-to-earnings-growth ratio of 1.20 and a beta of 0.42. The stock has a fifty day simple moving average of $207.05 and a 200-day simple moving average of $222.63. Biogen has a 52-week low of $187.16 and a 52-week high of $468.55. The company has a quick ratio of 1.70, a current ratio of 2.01 and a debt-to-equity ratio of 0.56.
A number of institutional investors have recently bought and sold shares of the business. Curi Wealth Management LLC raised its stake in shares of Biogen by 476.2% during the first quarter. Curi Wealth Management LLC now owns 121 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 100 shares during the last quarter. Avondale Wealth Management purchased a new stake in Biogen in the fourth quarter worth about $26,000. Equitec Proprietary Markets LLC purchased a new stake in shares of Biogen during the fourth quarter valued at approximately $27,000. EverSource Wealth Advisors LLC purchased a new stake in shares of Biogen during the fourth quarter valued at approximately $27,000. Finally, Amplius Wealth Advisors LLC purchased a new stake in shares of Biogen during the fourth quarter valued at approximately $28,000. 83.92% of the stock is owned by institutional investors and hedge funds.
Biogen Company Profile (Get Rating)
Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis.
- Get a free copy of the StockNews.com research report on Biogen (BIIB)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.